Skip to main content
. 2012 May;4(3):95–105. doi: 10.1177/1758834012444499

Figure 3.

Figure 3.

Average incremental cost (relative to biosimilar epoetin α) of 15 weeks’ treatment with the different erythropoiesis-stimulating agents (ESAs) across five weight-based dosing scenarios. Costs are based on population-weighted price per week in the EU G5 countries. QW, once weekly; Q3W, once every 3 weeks.